Concepedia

James Bell

JB

9

Publications

321

Citations

9

H-Index

2015

Active since

Affiliations

Novartis (Switzerland)(Current)

Eli Lilly (United States)

Hasselt University

Biogen (United States)

James Bell is an author at Novartis (Switzerland) specializing in health sciences, clinical trials, and clinical trial design.

Top concepts

HealthClinical TrialsClinical Trial DesignMedicineStatisticsMeta-analysisPublic HealthPharmacotherapyPatient SelectionClinical Trial Analysis

Publications per year

2015–2022

9

Publications

9

Choosing Estimands in Clinical Trials: Putting the ICH E9(R1) Into Practice

Bohdana Ratitch, James Bell, Craig Mallinckrodt et al. · Therapeutic Innovation & Regulatory Science · 2020 · 73 citations

Patient Selection, Clinical Endpoint, Clinical Evidence +7

Determinants of oral anticoagulation control in new warfarin patients: analysis using data from Clinical Practice Research Datalink

Ana Filipa Macedo, James Bell, C. McCarron et al. · Thrombosis Research · 2015 · 65 citations

Thrombosis, Venous Thrombosis, Cardiovascular Disease +13

Aligning Estimators With Estimands in Clinical Trials: Putting the ICH E9(R1) Guidelines Into Practice

Craig Mallinckrodt, James Bell, G. Liu et al. · Therapeutic Innovation & Regulatory Science · 2020 · 65 citations

Meta-analysis, Clinical Endpoint, Clinical Epidemiology +10

Defining Efficacy Estimands in Clinical Trials: Examples Illustrating ICH E9(R1) Guidelines

Bohdana Ratitch, Niti Goel, Craig Mallinckrodt et al. · Therapeutic Innovation & Regulatory Science · 2020 · 38 citations · Full text

Meta-analysis, Clinical Effectiveness, Clinical Trial Analysis +11

Marking 2-Years of New Thinking in Clinical Trials: The Estimand Journey

Christine Fletcher, Nanco Hefting, Melanie Wright et al. · Therapeutic Innovation & Regulatory Science · 2022 · 24 citations · Full text

Clinical Endpoint, Treatment Effect, Pharmacotherapy +18

Rows per page

1–5 of 9